s22

 From: \$22
 @pmc.gov.au>

 Sent: Monday, 9 December 2024 2:30 PM

 To: \$22
 @finance.gov.au>

 Cc: \$22
 @finance.gov.au>; Helpdesk-OIA <Helpdesk-OIA@pmc.gov.au>

 Subject: RE: \$22
 @finance.gov.au>; Helpdesk-OIA <Helpdesk-OIA@pmc.gov.au>

 analysis OBPR21-01229 [SEC=PROTECTED]
 \$200 PR21-01229 [SEC=PROTECTED]

PROTECTED

His22

I can confirm that the proposal OBPR assessed was in relation to the policy intent of providing funding to secure an mRNA capability.

Below is an excerpt from our email...

Thank you for sending your proposal for initial assessment. Based on the information provided, the OBPR considers the proposal is non-regulatory. Because the matter will be considered by a committee of Cabinet, a Regulation Impact Statement (RIS) is required. RIS requirements can be satisfied by noting there are "Nil regulatory impacts, OBPR21-01229" in the relevant Impacts table in the submission template.

Kind regards,



The department acknowledges and pays respect to the past, present and emerging Elders and Traditional Custodians of Country, and the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples.

From: ^{s22}	@finance.gov.au>	
Sent: Monday, 9 December 2024 2:22 PM		
To:s22	@pmc.gov.au>	
Cc: s22	@finance.gov.au>	

Subject: FW: \$22

the decision to not conduct a regulatory impact

analysis OBPR21-01229 [SEC=PROTECTED]

PROTECTED



Thanks for your time on the phone just now.

To clarify your advice below, the RIS assessment conducted under reference OBPR21-01229 was in response to the Department of Health's request for a policy impact analysis relating to the onshore mRNA vaccine manufacturing proposal.

Grateful if you can confirm my understanding of the 2021 assessment or share the advice provided to Health at the time (if at all possible).

Regards, s22

S22 | Director
Schedule 1AB | Financial Management Branch
Department of Finance
T: S22 | M: S22
E: S22 @finance.gov.au | FFSPRegs@finance.gov.au

A: 1 Canberra Avenue, Forrest ACT 2603

 From:
 \$22
 @pmc.gov.au>

 Sent:
 Friday, 29 November 2024 10:31 AM

 To:
 \$22
 @finance.gov.au>

 Subject:
 FW:
 \$22

 analysis
 OBPR21-01229 [SEC=PROTECTED]

PROTECTED

Hi**s22**

See below correspondence to Kelly Wood. I poorly copied your email address across in the original correspondence.

Cheers,

s22

s22

| Senior Adviser

Office of Impact Analysis



@pmc.gov.au

The department acknowledges and pays respect to the past, present and emerging Elders and Traditional Custodians of Country, and the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples.

From: S22

Sent: Friday, 29 November 2024 10:28 AM

To: 'Kelly.Wood@finance.gov.au' <<u>Kelly.Wood@finance.gov.au</u>>

•			
Cc: s22	@finance.gov.aul' s22	@finance.gov.a	iul>;
s22	@finance.gov.au; Helpo	lesk-OIA < <u>Helpdesk-OIA@</u>	0pmc.gov.au>;s22
s22	@pmc.gov.a	<u>u</u> >; s22	@pmc.gov.au>; s22
s22 🧕	opmc.gov.au>		
Subject: FW:	s22	the decision to not cond	luct a regulatory impact
		1	

analysis OBPR21-01229 [SEC=PROTECTED]

Hi Kelly,

S22 from your Department has provided us with correspondence **S22** regarding a Regulatory Impact Statement decision. As noted in the ES, OIA assessed the original proposal as not requiring a Regulation Impact Statement (quote below) under the old OBPR framework (https://oia.pmc.gov.au/sites/default/files/2021-06/australian-government-guide-to-regulatory-impact-analysis.pdf).


A regulatory impact analysis is not required as the Regulations only apply to non-corporate Commonwealth entities and do not adversely affect the private sector.

Under the OBPR Guide and under Cabinet settings, OIA viewed the direct impact on Moderna as 'non-regulatory in nature', due to the pre-existing framework which puts in place financial obligations in terms of receiving Commonwealth funding. We note that Finance would be best placed to provide advice on the decision making around Commonwealth funding.

OIA is happy to work closely with Finance in drafting a response.


Kind regards,

s22



From: Helpdesk-OIA < <u>Helpdesk-OIA@</u>	pmc.gov.au>
Sent: Wednesday, 27 November 2024	4 4:12 PM
To: OIA - Team 1 < <u>OIA-Team1@pmc.</u>	<u>gov.au</u> >
Cc: s22 @pm	c.gov.au>; <mark>s22</mark>
@pmc.gov.au>	
Subject: S22	the decision to not conduct a regulatory impact analysis

As discussed - handing over to the Number One Team in the OIA



OFFICIAL:Sensitive

Hi OIA

s22 raising concerns about the decision to not conduct a regulatory impact analysis in relation to the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024;* in particular, the amendment to Schedule 1AB (table item 531) that provides legislative authority to provide funding for vaccines and treatments program to develop and maintain Australia's onshore capability to manufacture mRNA vaccines and products, including by purchasing mRNA vaccines and products manufactured onshore.

I would be grateful for confirmation that OIA did not require a RIS for this measure when it was considered by Government, and the reasons for that, and that there was no further requirement to undertake an RIA when legislative authority was sought.

Kind regards

s22

s22 | Principal Legal Officer

Public Administrative Law | Legal and Assurance Branch

Corporate Division | Department of Finance

- P: s22
- E: \$22 @finance.gov.au

A: One Canberra Avenue, FORREST ACT 2603

IMPORTANT: This message, and any attachments to it, contains information that is confidential and may also be the subject of legal professional or other privilege. If you are not the intended recipient of this message, you must not review, copy, disseminate or disclose its contents to any other party or take action in reliance of any material contained within it. If you have received this message in error, please notify the sender immediately by return email informing them of the mistake and delete all copies of the message from your computer system.

Be careful with this message External email. Do not click links or open attachments unless you recognise the sender and know the content is safe.

IMPORTANT: This message, and any attachments to it, contains information that is confidential and may also be the subject of legal professional or other privilege. If you are not the intended recipient of this message, you must not review, copy, disseminate or disclose its contents to any other party or take action in reliance of any material contained within it. If you have received this message in error, please notify the sender immediately by return email informing them of the mistake and delete all copies of the message from your computer system.